Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th
CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...
Addiction
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key...
BrainsWay Announces Appointment of Ido Marom as CFO
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
CHATHAM, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
Refinanced Loan Extends Maturity to December 2024SEATTLE and VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from...
Scotiabank donates $1.35M to the MUHC Foundation to create a Montreal without hepatitis C
The transformative gift supports Montréal sans HépC, an ambitious community-based program to prevent and cure hepatitis C cases in Montreal...
Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business
Adial to receive potential development and commercial milestone payments of up to $83 million on the first three compounds plus...
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome Tel Aviv, Israel / Vancouver, Canada, May...
Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical...
National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders
ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced...
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by...
Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits
SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients...
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada,...
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE)...
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of...
Inovalon Expands Revenue Cycle Data Analytics Software to Support All EDI Clearinghouses for Healthcare Providers
SaaS Solution Delivers up to 93% First-Pass Yield and Prevents Revenue Leakage While Improving Cash Flow by up to 15%BOWIE,...